News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
741,768 Results
Type
Article (43784)
Company Profile (318)
Press Release (697653)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210980)
Career Advice (2107)
Deals (36757)
Drug Delivery (123)
Drug Development (83415)
Employer Resources (176)
FDA (16821)
Job Trends (15500)
News (357340)
Policy (34125)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2612)
Accelerated approval (31)
Adcomms (26)
Allergies (148)
Alliances (51584)
ALS (173)
Alzheimer's disease (1690)
Antibody-drug conjugate (ADC) (322)
Approvals (17084)
Artificial intelligence (537)
Autoimmune disease (156)
Automation (39)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (21)
Biosimilars (194)
Biotechnology (188)
Bladder cancer (157)
Brain cancer (60)
Breast cancer (648)
Cancer (4873)
Cardiovascular disease (413)
Career advice (1786)
Career pathing (37)
CAR-T (285)
CDC (47)
Celiac Disease (2)
Cell therapy (755)
Cervical cancer (36)
Clinical research (71145)
Collaboration (1756)
Company closure (4)
Compensation (1165)
Complete response letters (62)
COVID-19 (2784)
CRISPR (94)
C-suite (868)
Cystic fibrosis (148)
Data (6252)
Decentralized trials (2)
Denatured (36)
Depression (134)
Diabetes (506)
Diagnostics (6773)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (259)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (233)
Earnings (91886)
Editorial (60)
Employer branding (21)
Employer resources (155)
Events (120212)
Executive appointments (998)
FDA (19964)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1483)
Gene editing (201)
Generative AI (45)
Gene therapy (614)
GLP-1 (1013)
Government (4802)
Grass and pollen (7)
Guidances (384)
Healthcare (19057)
HIV (58)
Huntington's disease (45)
IgA nephropathy (83)
Immunology and inflammation (261)
Immuno-oncology (58)
Indications (111)
Infectious disease (3053)
Inflammatory bowel disease (194)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (253)
Interviews (326)
IPO (16920)
IRA (57)
Job creations (4069)
Job search strategy (1498)
JPM (64)
Kidney cancer (16)
Labor market (85)
Layoffs (575)
Leadership (33)
Legal (8423)
Liver cancer (92)
Longevity (15)
Lung cancer (654)
Lymphoma (378)
Machine learning (43)
Management (60)
Manufacturing (820)
MASH (169)
Medical device (13855)
Medtech (13908)
Mergers & acquisitions (20907)
Metabolic disorders (1302)
Multiple sclerosis (160)
NASH (17)
Neurodegenerative disease (321)
Neuropsychiatric disorders (91)
Neuroscience (2941)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4562)
Now hiring (67)
Obesity (615)
Opinion (283)
Ovarian cancer (167)
Pain (215)
Pancreatic cancer (228)
Parkinson's disease (281)
Partnered (34)
Patents (502)
Patient recruitment (493)
Peanut (59)
People (60896)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22084)
Phase 2 (31282)
Phase 3 (23437)
Pipeline (5307)
Policy (297)
Postmarket research (2655)
Preclinical (9383)
Press Release (68)
Prostate cancer (239)
Psychedelics (50)
Radiopharmaceuticals (285)
Rare diseases (865)
Real estate (6305)
Recruiting (72)
Regulatory (25374)
Reports (52)
Research institute (2437)
Resumes & cover letters (361)
Rett syndrome (27)
RNA editing (17)
RSV (77)
Schizophrenia (155)
Series A (244)
Series B (193)
Service/supplier (11)
Sickle cell disease (98)
Special edition (24)
Spinal muscular atrophy (160)
Sponsored (42)
Startups (3765)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (96)
The Weekly (78)
Vaccines (1032)
Venture capital (90)
Weight loss (403)
Women's health (91)
Worklife (18)
Date
Today (153)
Last 7 days (596)
Last 30 days (2132)
Last 365 days (30425)
2026 (3433)
2025 (30679)
2024 (35767)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (83)
Alaska (7)
Arizona (316)
Arkansas (14)
Asia (42149)
Australia (6747)
California (11346)
Canada (3304)
China (1137)
Colorado (480)
Connecticut (478)
Delaware (339)
Europe (90336)
Florida (1693)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (877)
India (68)
Indiana (529)
Iowa (22)
Japan (440)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1390)
Massachusetts (8170)
Michigan (327)
Minnesota (632)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (123)
New Hampshire (78)
New Jersey (3016)
New Mexico (29)
New York (2993)
North Carolina (1473)
North Dakota (8)
Northern California (5533)
Ohio (334)
Oklahoma (22)
Oregon (46)
Pennsylvania (2294)
Puerto Rico (24)
Rhode Island (47)
South America (1175)
South Carolina (67)
South Dakota (1)
Southern California (4417)
Tennessee (174)
Texas (1752)
United States (40317)
Utah (337)
Vermont (1)
Virginia (276)
Washington D.C. (81)
Washington State (928)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
741,768 Results for "idera pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”) prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
February 8, 2026
·
7 min read
Press Releases
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
January 16, 2026
·
6 min read
Press Releases
China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering
January 12, 2026
·
3 min read
Bio NC
Idera Pharmaceuticals Announces Name Change to Aceragen, Inc. and Provides Near-Term Strategic Outlook
Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA), a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases, today announced the Company has changed its name and symbol to Aceragen, Inc. (“Aceragen,” the “Company,” “we,” “us,” or “our”) and “ACGN”.
January 17, 2023
·
8 min read
Press Releases
CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN
January 16, 2026
·
3 min read
Deals
Idera Pharmaceuticals Acquires Aceragen
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today announced it has completed the acquisition of Aceragen, Inc. (“Aceragen”), a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there are limited or no available treatments.
September 28, 2022
·
12 min read
Press Releases
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
December 24, 2025
·
12 min read
Press Releases
Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026
January 7, 2026
·
3 min read
Press Releases
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2025 Results and Provides Business Update
November 13, 2025
·
11 min read
Business
Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results for the third quarter ended September 30, 2022.
November 14, 2022
·
12 min read
1 of 74,177
Next
